Podcasts

Join Professors Meg Jardine and Rajiv Agarwal as they discuss their highlights of ASN 2023!

Join Professor George Bakris, Professor of Medicine and Director of the American Society of Hypertension’s Comprehensive Hypertension Centre, University of Chicago and Professor Darren McGuire, a Professor in the Department of Internal Medicine at the University of Texas Southwestern Medical School as they discuss the main findings of three publications from the monthly literature searches in September and October, and what they mean for clinical practice across cardiometabolic disease.

The first publication’s analysis aimed to evaluate the efficacy and safety of empagliflozin versus placebo according to MRA use at baseline in EMPULSE trial. The Second publication assessed the relationship between HbA1c and body weight reductions with tirzepatide treatment (5, 10 or 15 mg) across the SURPASS clinical trial programme and the third publication evaluated the efficacy and safety of orforglipron in adults with obesity, or with overweight plus at least one weight-related coexisting condition, and without T2D.

Join Professor George Bakris, Professor of Medicine and Director of the American Society of Hypertension’s Comprehensive Hypertension Centre, University of Chicago and Professor Richard Donnelly, Emeritus Professor of Medicine and Editor-in-Chief at the University of Nottingham, United Kingdom, as they discuss the main findings of three publications from the monthly literature searches in July and August and what they mean for clinical practice across cardiometabolic disease.

Join Professor Naveed Sattar, Honorary Consultant in Metabolic Medicine at the Glasgow Royal Infirmary and Professor Subodh Verma, an internationally renowned cardiac surgeon-scientist and Professor at the University of Toronto as they discuss the main findings of three publications from our May / June literature search.

The first of these is a paper by Tan et al. This systematic review and meta-analysis aimed to assess the efficacy and safety of tirzepatide for weight loss in patients with overweight or obesity.

The second is by Sharma et al on the cardiac and kidney benefits of Empagliflozin in HF across the spectrum of kidney function: Insights from the EMPEROR-Preserved trial

The third and final publication we will be discussing is by Gupta et al on the racial differences in the quality of life in patients with HF treated with SGLT2 inhibitors.

Join Professor Meg Jardine, Director of the NHMRC Clinical Trials Centre at the University of Sydney, and Director of the CTC’s Kidney Health Research team and Hiddo Heerspink, Professor of Clinical Trials and Personalised Medicine at the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen while they discuss the main findings of three publications from the monthly literature searches in March and April and what they mean for clinical practice. The first of these studies examines the effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes. The second publication is on the outcomes with finerenone in participants with stage 4 CKD and Type 2 Diabetes. The third and final publication discussed is a mini review summarising recent data on new treatments for heart failure with reduced ejection fraction.

You can find summary slides decks of all three papers discussed today at cardiometabolicforum.com

Join Professor David Wheeler, Professor of Kidney Medicine at University College London and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust and Richard Donnelly, Emeritus Professor of Medicine at the University of Nottingham, UK, as they discuss three papers from the world of cardiometabolic disease research. The first publication describes the development and validation of CKD 'Add-ons’ for existing CVD prediction models. The second paper discuses the efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status. The second publication is an analysis from the FIDELITY database – a pooled dataset from the FIDELIO-DKD and FIGARO-DKD trials – which assessed finerenone in patients with T2D and either advanced CKD or earlier-stage CKD with high CV risk. The final publication we will be discussing is a substudy of the ARTS-DN trial, which assessed the effects of finerenone on 24-h ambulatory BP in patients with CKD and T2D.

You can find summary slides decks of both papers discussed today at cardiometabolicforum.com